Endocardial dispersive electrode for use with a monopolar RF ablation pen

Information

  • Patent Grant
  • 7871409
  • Patent Number
    7,871,409
  • Date Filed
    Monday, February 2, 2009
    16 years ago
  • Date Issued
    Tuesday, January 18, 2011
    14 years ago
Abstract
Methods and devices for forming a lesion in a target tissue having a cavity within. A first RF electrode and a second RF electrode can be coupled to opposite poles of an RF current source. The second electrode can be inserted into the tissue cavity and expanded to contact the target tissue from within. The first electrode can be externally disposed against the target tissue while applying RF current between the first and second electrodes to ablate the target tissue. Some methods are directed to ablating tribiculated atrial wall tissue to treat atrial fibrillation. The second electrode can contact the tribiculated tissue directly from within to provide a direct path between the two electrodes. In some methods, the second electrode is inserted through an incision made to remove an atrial appendage. The methods can provide deeper, narrower lesions relative to those made using remote, indifferent electrodes. Atrial fibrillation ablation procedures can be performed using the invention, requiring fewer incisions than conventional methods.
Description
FIELD OF THE INVENTION

The present invention relates generally to devices for cardiac surgery, and more specifically to devices for ablation of cardiac tissue.


BACKGROUND OF THE INVENTION

The present invention is directed toward treatment of tachyarrhythmias, which are heart rhythms in which one or more chambers of the heart exhibit an excessively fast rhythm. In particular, the present invention is directed toward treatment of tachycardias, which are due to the presence of ectopic foci within the cardiac tissue or due to the presence of aberrant condition pathways within the cardiac tissue.


There are many medical treatments that involve instances of cutting, ablating, coagulating, destroying, or otherwise changing the physiological properties of tissue. These techniques can be used beneficially to change the electrophysiological properties of tissue. For example, ablation of cardiac tissue can be used to cure various cardiac conditions. Normal sinus rhythm of the heart begins with the sinoatrial node (or “SA node”) generating a depolarization wave front. The impulse causes adjacent myocardial tissue cells in the atria to depolarize, which in turn causes adjacent myocardial tissue cells to depolarize. The depolarization propagates across the atria, causing the atria to contract and empty blood from the atria into the ventricles. The impulse is next delivered via the atrioventricular node (or “AV node”) and the bundle of HIS (or “HIS bundle”) to myocardial tissue cells of the ventricles. The depolarization of these cells propagates across the ventricles, causing the ventricles to contract. This conduction system results in the described, organized sequence of myocardial contraction leading to a normal heartbeat.


Sometimes aberrant conductive pathways develop in heart tissue, which disrupt the normal path of depolarization events. For example, anatomical obstacles in the atria or ventricles can disrupt the normal propagation of electrical impulses. These anatomical obstacles (called “conduction blocks”) can cause the electrical impulse to degenerate into several circular wavelets that circulate about the obstacles. These wavelets, called “reentry circuits,” disrupt the normal activation of the atria or ventricles.


The aberrant conductive pathways create abnormal, irregular, and sometimes life-threatening heart rhythms, called arrhythmias. An arrhythmia can take place in the atria, for example, as in atrial tachycardia, atrial fibrillation or atrial flutter. The arrhythmia can also take place in the ventricle, for example, as in ventricular tachycardia.


The lesions used to treat atrial fibrillation, are typically long and thin and are carefully placed to interrupt the conduction routes of the most common reentry circuits. More specifically, the long thin lesions are used to create a maze pattern that creates a convoluted path for electrical propagation within the left and right atria. The lesions direct the electrical impulse from the SA node along a specified route through all regions of both atria, causing uniform contraction required for normal atrial transport function. The lesions finally direct the impulse to the AV node to activate the ventricles, restoring normal atrioventricular synchrony. Several surgical approaches have been developed with the intention of treating atrial fibrillation. One particular example is known as the “maze procedure,” as is disclosed by Cox, J L et al. in “The surgical treatment of atrial fibrillation. I. Summary” Thoracic and Cardiovascular Surgery 101(3), pp. 402-405 (1991); and also by Cox, J L in “The surgical treatment of atrial fibrillation. IV. Surgical Technique”, Thoracic and Cardiovascular Surgery 101(4), pp. 584-592 (1991), both of which are incorporated by reference herein in their entireties. In general, the “maze” procedure is designed to relieve atrial arrhythmia by restoring effective atrial systole and sinus node control through a prescribed pattern of incisions about the tissue wall. In the early clinical experiences reported, the “maze” procedure included surgical incisions in both the right and the left atrial chambers. However, more recent reports predict that the surgical “maze” procedure may be substantially efficacious when performed only in the left atrium, such as is disclosed in Sueda et al., “Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated With Mitral Valve Disease” (1996), which is incorporated herein by reference in its entirety.


When modifying the electrophysiological properties of cardiac tissue by ablation, or by other means of destroying tissue to create lesions, physicians must carefully place the lesions. Otherwise, tissue will be unnecessarily destroyed. In addition, the heart is in close proximity to nerves and other nervous tissue and the destruction of this tissue will result in severe harm to the patient. Anatomical methods are used to locate the areas to be ablated or otherwise modified. In other words, the physician locates key structures such as the mitral valve annulus and the pulmonary veins. Lesions are typically formed that block propagations near these structures. Additional lesions are then formed which connect these lesions and complete the so-called “maze pattern.” However, the exact lesion pattern, and number of lesions created, can vary from patient to patient.


The surgical “maze procedure” as performed in the left atrium generally includes forming vertical incisions from the two superior pulmonary veins and terminating in the region of the mitral valve annulus, traversing the inferior pulmonary veins en route. An additional horizontal line also connects the superior ends of the two vertical incisions. Thus, the atrial wall region bordered by the pulmonary vein ostia is isolated from the other atrial tissue. In this process, the mechanical sectioning of atrial tissue eliminates the precipitating conduction to the atrial arrhythmia by creating conduction blocks within the aberrant electrical conduction pathways.


Injection of alcohol into heart tissue has also been employed to ablate cardiac tissue. Alcohol may be delivered to blood vessels supplying the tissue to be ablated, as described in “Transcoronary Chemical Ablation of Arrhythmias”, by Nellens et al, Pace Vol. 15, pages 1368-1373, September 1992. Alternatively, alcohol can be delivered directly to the tissue to be ablated by means of a needle inserted through a catheter, as described in “Chemical Ablation by Subendocardial Injection of Ethanol via Catheter—Preliminary Results in the Pig Heart”, by Weismuller et al, European Heart Journal, Volume 12, pages 1234-1239, 1991.


Although successful at treating AF, the surgical maze procedure is quite complex and is currently performed by only a few skilled cardiac surgeons in conjunction with other open-heart procedures. Tools that could reliably duplicate the Maze incisions by other means (e.g. radio frequency, laser, microwave, ultrasound energy) will reduce the time and invasiveness required for the maze procedure and make it more accessible to more surgeons. Problems faced by these methods, however, include (a) the creation of continuous, linear lesions in the atria for the prevention of atrial fibrillation, (b) minimization of clotting and thromboembolism, (c) the effect of heat loss due to circulating blood, (d) minimization of lesion width and minimization of atrial debulking, (e) conforming to an irregular myocardial thickness, (f) adaptability to a variety of lesion geometries and (g) usefulness from either the endocardial surface of an open heart, or the epicardial surface of a beating heart.


One particular procedure, the monopolar RF ablation of cardiac atrial tissue to treat atrial fibrillation, causes wide, shallow lesions, due to current dispersion through the tissue. In heavily tribiculated tissue, monopolar ablation is only feasible endocardially. An epicardial approach using conventional methods will not efficiently transfer energy into the deep tissue folds, due to that tissue being out of the conductive path between the external epicardial electrode and the remote indifferent electrode. Bipolar hemostats have been used to concentrate the current through a direct tissue path between closely spaced electrodes to provide improved ablation through smooth or heavily tribiculated tissue. However, the bipolar hemostats require significant tissue cutting to provide complete access to necessary lesion sites.


Some tissue cutting is required in a Maze procedure. In particular, the atrial appendages are typically removed. Monopolar RF cardiac ablation requires significant additional tissue cutting in order to position the electrode in the proper positions to perform endocardial ablations.


What would be desirable are methods that would reduce tissue cutting and improve the efficacy of epicardial ablation. What would be advantageous are devices that direct RF current along the desired transmural path, creating narrower and deeper lesions.


SUMMARY OF THE INVENTION

The present invention includes devices and methods for ablation of cardiac tissue in which a hand-held, monopolar RF ablation device is used to ablate cardiac tissue in conjunction with an expandable endocardial electrode inserted into a heart chamber and urged against the chamber wall. The endocardial electrode can be expandable or inflatable and have a conductive surface. The endocardial electrode may be inserted through a small incision made in the heart chamber wall and/or through the opening made by the removal of the atrial appendage. The electrode can then be expanded or inflated, urging the conductive surface against the endocardium.


A monopolar RF ablation device can then be drawn along the desired lesion line on the epicardium. A current path is thus formed between the epicardial RF device and the expanded surface electrode disposed against the endocardium. The direct path between the external monopolar RF electrode and the endocardial surface internal electrode can provide a narrower, deeper lesion relative to the lesion created using a current path between the RF electrode and an external, indifferent electrode. The incision required to insert the expandable or inflatable electrode can be significantly smaller than that required to insert and successfully maneuver the monopolar RF electrode endocardially.


The monopolar electrode tissue-contacting surface can be connected to one pole of a radio frequency generator while the other pole of the generator is connected to a large surface, endocardial electrode. In one embodiment of the invention, the epicardial monopolar electrode is a conventional radio frequency ablation device such as the Cardioblate® pen available Medtronic, Inc.


The present invention includes methods for forming a lesion in a target tissue having a cavity within. The methods can include providing a first RF electrode coupled to a RF current source and a second RF electrode electrically coupled to form a ground path for the first RF electrode, wherein the second RF electrode is electrically conductive and expandable, wherein the second electrode has a first, unexpanded configuration and a second, expanded configuration. The second electrode can be inserted into the tissue cavity and expanded to the second configuration to contact the target tissue from within the cavity. The first electrode can be disposed against the target tissue while applying RF current between the first and second electrodes to ablate the target tissue.


The present invention includes methods for treating atrial fibrillation that do not require making any incisions in the right or left atria other than those to remove the left and/or right atrial appendages. The methods can include making lesion paths of the Maze, Maze 3 or Modified Maze 3 procedures, while performing only the incisions to remove the atrial appendages. The methods can include making lesions along the paths described in the: Cox, J L et al.; Cox, J L; and Sueda et al. publications, previously incorporated by reference in the present application.


In one method, an incision is made to remove the right atrial appendage and the method does not include making any other incisions in the right atrium. One such method does not include making an incision from the right atrial appendage incision toward the inferior vena caval orifice. Another such method does not include making a posterior longitudinal incision starting caudal to the superior caval cannulation site at the dorsal aspect of the right atrium.


In another method, an incision is made to remove the left atrial appendage, and the method does not include making any other incisions in the left atrium. One such method does not include making a standard atriotomy in the inter-atrial groove between the left and right atria.


One device includes a shaft and an electrode including an envelope having an interior and an electrically conductive flexible surface disposed near the shaft distal region. The second electrode surface can have a first configuration having a first interior volume within the conductive surface and a second, expanded configuration having a second interior volume within the conductive surface, with the second volume being greater than the first volume.


In some devices, the electrically conductive surface includes an outer metallic layer disposed over a polymeric layer. Some electrodes include an outer metallic mesh disposed over a polymeric layer. The polymeric layer can be substantially resistant to fluid permeation, such that the polymeric layer is inflatable. The envelope can be formed of an electrically conductive polymer. Some envelopes according to the present invention are porous, and the electrically conductive surface can be the outer surface an electrically conductive porous mesh. Some meshes are metallic meshes.


Some device embodiments have a fluid lumen extending through the shaft, which can be used to inflate the envelope. Other embodiments have envelopes biased to expand when unconstrained. Still other embodiment envelopes include shape memory materials that expand when heated to body temperature.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a prior art, fragmentary, cross-sectional view of a heart chamber wall having tribiculated tissue, the wall being partially ablated using an external RF electrode and a remote, indifferent electrode;



FIG. 2 is a fragmentary, cross-sectional view of the tribiculated heart chamber wall of FIG. 1, being ablated using the RF electrode of FIG. 1 and an internal, expandable surface electrode contacting the tribiculated tissue;



FIG. 3 is a diagrammatic, longitudinal cross-sectional view of one device having an expandable surface electrode, shown in an un-expanded configuration;



FIG. 4 is a diagrammatic, longitudinal cross-sectional view of another device having an expandable surface electrode, shown in an un-expanded configuration;



FIG. 5 is a diagrammatic, longitudinal cross-sectional view of yet another device having an expandable surface electrode, shown in an un-expanded configuration within a retractable delivery sheath;



FIG. 6 is a diagrammatic, longitudinal cross-sectional view of still another device having an expandable surface electrode, shown in an un-expanded configuration within a retractable delivery sheath;



FIG. 7 is a diagrammatic, longitudinal cross-sectional view of a device having an expandable surface electrode, shown in an expanded configuration;



FIG. 8 is a fragmentary, cross-sectional view of an envelope formed of an electrically conductive material;



FIG. 9 is a fragmentary, cross-sectional view of an envelope formed of an electrically conductive material layer formed over another, more interior material;



FIG. 10 is a fragmentary, cross-sectional view of an envelope formed of an electrically conductive mesh formed over another, more interior material; and



FIG. 11 is a fragmentary, side view of an envelope formed of an electrically conductive porous mesh.





DETAILED DESCRIPTION OF THE INVENTION


FIG. 1 illustrates a prior art method for ablating cardiac tissue in the atria. In particular, a tribiculated region of the atria is illustrated. An atrial region 30 is illustrated, having an atrial wall 32, an interior 34, and tribiculated tissue 36 is illustrated, having gaps or cavities 37 disposed between the tribiculated tissue regions. A monopolar electrode 40 is illustrated, coupled to an RF energy source 42. A lesion area 38 formed from the ablation is also illustrated. In FIG. 1, a remote, indifferent electrode (not illustrated in FIG. 1) provides the return path for the RF energy supplied by monopolar electrode 40. As may be seen from inspection of FIG. 1, lesion area 38 is fairly wide, and does not penetrate into tribiculated tissue regions 36. The shallow and insufficiently deep lesions are formed due to the RF current dispersion, indicated at 44, as RF energy takes a path to the indifferent electrode that does not include penetrating directly into atrial wall 32. As maybe seen from inspection of FIG. 1, monopolar ablation of some tissue regions may not be feasible using a monopolar electrode, due to the shallow penetration. In such cases, endocardial ablation, using electrode 40, may be required.



FIG. 2 illustrates atrial region 30 of FIG. 1, using devices and methods according to the present invention. Tribiculated tissue regions 36 may be seen, as discussed with respect to FIG. 1. In FIG. 2 however, a second electrode 46 may be seen, having an envelope surface 48 contacting the tissue of atrial wall 32 and tribiculated tissue regions 36. Second electrode 46 may be described as an envelope or membrane, in various embodiments. Second electrode 46 may be seen to contact tribiculated tissue 36 and other endocardial tissue directly, providing a short, direct current path, indicated at 50, between second electrode 46 and a monopolar electrode 40. As a result of the more direct current path, a deeper and narrower lesion 52 may be formed between monopolar electrode 40 and second electrode 46. As illustrated in FIG. 2, the present invention can provide a lesion formed entirely through the heart chamber wall, using an external electrode and the second, internal electrode.



FIG. 3 illustrates a device 70 that can be used to facilitate ablating cardiac tissue. Device 70 includes a device shaft 72 having an interior 84, a proximal region 74, and a distal region 76. An expandable envelope 78 may be seen affixed to shaft distal region 76. Envelope 78 is shown in a first, unexpanded configuration, having folds 80 and an internal volume, indicated at 82. Envelope 78 further includes a proximal mouth 77, secured to shaft distal region 77. As used herein, “expandable” refers to the envelope having an unexpanded and an expanded configuration, wherein the expanded configuration has a larger internal volume than the first configuration. The term “expandable” does not require that the envelope be elastic or stretchable in any way.


While some embodiments include a proximal shaft, other embodiments have no shaft. Some embodiments utilize the proximal mouth of the envelope or balloon to expand or inflate the envelope or balloon. In such embodiments, the balloon or envelope can be inserted into the heart chamber through an opening and inflated through a fluid supplied to the balloon proximal mouth.


Shaft 72 may be solid in some embodiments and hollow in other embodiments, carrying an inflation lumen within. In some embodiments, shaft 72 has a length of between about 12 and 18 inches. Some embodiments have a shaft length less than 12 inches, while other embodiments have a shaft length less than 6 inches. Some shafts have an outer diameter of between about 20 Fr. and 30 Fr. Shaft 72, and other shafts according to the present invention may be of shaft or tube materials well known to those skilled in the biomedical arts. Exemplary shaft materials include silicone, PEBAX, polyurethane, and PVC.



FIG. 4 illustrates another device 90 that can be used according to the present invention. Device 90 includes a shaft 92 having a proximal region 94 and a distal region 96. Shaft 92 further includes a lumen 100 within, carrying a proximal push rod 102 having a distal flange 104 attached to the push rod. An envelope 98 may be seen, in an unexpanded configuration within shaft lumen 100. In use, push rod 102 can be used to force envelope 98 out of shaft 92, allowing envelope 98 to expand. Envelope 98 may be self-expanding in some embodiments, and require fluid inflation, in other embodiments.



FIG. 5 illustrates still another device 120 having a shaft 128 having an envelope 132 secured to a shaft distal region 129. Envelope 132 may be seen to be in an unexpanded configuration. Envelope 132 may be seen to be in a compressed, folded state. Device 120 further includes an outer delivery sheath or sleeve 134 having a distal region 124 and a proximal region 126. Sleeve 134 can be proximally retracted from shaft 128 bearing envelope 132, or shaft 128 and envelope 132 can be distally urged out of delivery sleeve 134. In some embodiments, envelope 132 is self-expanding. In other embodiments, envelope 132 is inflated with fluid supplied through a lumen extending through shaft 128.



FIG. 6 illustrates still another device 140 having a delivery sheath 142 having distal region 144 and proximal region 146. An expandable envelope 150 may be seen, secured to a shaft 148. Shaft 148 and envelope 150 are both disposed within delivery sheath 142. In some embodiments, envelope 150 is biased to expand radially outward to form a spherical or bulbous shape, when unconstrained by outer sheath 142. In some embodiments, the envelope, for example, envelope 150, may be urged distally from a constraining tube, for example, sheath 142. After being distally urged from the outer tube, the envelope may be radially expanded and the outer tube used as a catheter to guide the now expanded envelope to the target site.



FIG. 7 illustrates device 70 of FIG. 3, in a second, expanded configuration. Device 70 may be seen to have a much larger envelope internal volume 82. Envelope 78 may be seen to be in a significantly expanded configuration relative to that seen in FIG. 3. In some embodiments, envelope 78 is self-expanding. In other embodiments, envelope 78 is inflated with fluid provided through a lumen provided through shaft 72, within shaft interior 84. In some methods, saline is used as the inflation fluid.



FIG. 8 illustrates a section of envelope material 160, wherein the entire thickness of the envelope material is electrically conductive. One such envelope material includes a conductive polymer.



FIG. 9 illustrates another envelope 162. Envelope 162 includes an inner layer 164 and an outer layer 166. In some embodiments, inner layer 164 is a polymeric, substantially nonconductive material. Outer layer 166 can be an electrically conductive material, for example, a metallic film. In some embodiments, envelope 162 is formed of Mylar, having a metallic film disposed over a polymeric layer.



FIG. 10 illustrates yet another envelope section 168 having an inner, substantially contiguous layer 170 and an outer mesh 172. In some embodiments, inner layer 170 is a polymeric layer that is substantially impervious to fluid flow, enabling the envelope to be fluid expanded. In some envelopes, mesh 172 is an electrically conductive, metallic mesh. Mesh 172 can be formed of Nitinol in some embodiments and stainless steel in other embodiments. In still other embodiments, electrically conductive mesh 172 is formed of an electrically conductive polymer. In some envelopes, mesh 172 is formed of a material biased to expand outwardly when unconstrained. In other embodiments, mesh 172 is formed of a shape memory material, set to expand outwardly when heated toward body temperature from room temperature. For the purposes of the present invention, room temperature may be defined as about 70 degrees Fahrenheit.



FIG. 11 illustrates still another envelope section 174, having a porous mesh including braids or strands 176 having pores 178 disposed therebetween. In embodiments having a porous mesh, the mesh itself may be self-expandable or may be expanded through an inflation envelope disposed within the mesh.


In one method according to the present invention, a first RF electrode is provided, coupled to a RF current source. A second RF electrode is also provided and coupled to form a ground path for the first RF electrode. The second electrode can include an electrically conductive envelope surface defining an interior volume within. The envelope can have a first, unexpanded configuration and a second, expanded configuration. The second configuration can have an interior volume greater than the first, unexpanded configuration. An incision can be made in a heart chamber wall. A preferred use of the present invention is to ablate atrial wall tissue. One such incision is an incision made to remove an atrial appendage. Such incisions are typically made as part of a maze procedure.


After the incision is made, the second electrode can be inserted through the incision and into the heart chamber interior. The second electrode can then be expanded to urge the second electrode conductive surface to contact a target region of the heart chamber endocardium. The first electrode can be disposed against the target region epicardium while applying RF current through the first electrode.


A short, direct current path is thus formed between the first electrode on the epicardium and the expanded surface electrode bearing against the endocardium. The second electrode can be urged against tribiculated tissue to provide direct contact with the second electrode and therefore provide a short and direct current path directed through the tribiculated tissue. A lesion resulting from the current path formed between the first electrode and the second, interior electrode, can thus be both deeper and narrower than lesions formed using the external electrode and a remote indifferent electrode.


In some methods, the second electrode is biased to expand when unconstrained, and is freed from constraint after being inserted into the heart chamber through the incision. In some such methods, a sleeve or delivery tube is retracted from about the constrained second electrode. While some electrodes are simply biased to expand outward when unconstrained, other internal electrodes are formed of a shape memory material that expands when heated toward body temperature.


Some methods include providing a fluid expandable or inflatable envelope. In such methods, a fluid, for example, saline, can be injected into the envelope interior to expand the envelope to its fully expanded shape.


Applicant believes that the present invention provides novel methods for forming lesions entirely through the atrial wall using a first, external electrode on the epicardium and a second, expanded surface internal electrode on the endocardium, simultaneously. This may be contrasted with using an electrode drawn over the endocardial surface, for example, a pen electrode. While forming a lesion using an inserted pen electrode may be efficacious, a large incision must be made through the heart chamber wall in order to properly direct the drawing of the pen electrode across the endocardium. Using the present invention, an incision only large enough to insert the expandable or inflatable envelope need be made.


Applicant believes that target sites in the entire right and left atrial free wall regions may be ablated using RF ablation, and entirely through the atrial wall, where ablating these sites does not require making an incision in the right atrium from the excised atrial appendage parallel to the right atrioventricular groove toward the inferior vena cava (IVC), an incision from about 1 cm, above the IVC cannulation site to the top of the atrioventricular groove, or in the left atrium in the interatrial groove.


In general, the present invention provides methods for forming lesions in target tissue having a cavity within. In the general case of the invention, a first electrode is coupled to a RF current source and a second RF electrode is electrically coupled to form a ground path for the first RF electrode. The second electrode can be inserted into the tissue cavity and expanded to contact the target tissue from within the cavity. The first electrode can then be disposed against the target tissue from the outside, while applying RF current through the first electrode to ablate the target tissue.


It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited, and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses are intended to be encompassed by the claims attached hereto. The entire disclosure of each patent and publication cited herein is incorporated by reference, as if each such patent or publication were individually incorporated by reference herein.

Claims
  • 1. A method for forming a lesion in a target tissue having a cavity within, the method comprising: providing a first RF electrode coupled to one pole of an RF current source;providing a second RF electrode electrically coupled to the other pole of the RF current source, wherein the second RF electrode has an electrically conductive expandable surface defining an expandable interior volume;inserting the second electrode into the tissue cavity;expanding the interior volume of the second electrode such that the electrically conductive expandable surface contacts the target tissue from within the cavity; anddisposing the first electrode against the target tissue while applying RF current between the first and second electrodes to ablate the target tissue.
  • 2. A method as in claim 1, wherein the target tissue is atrial tissue and the cavity is the atria, wherein the expanding includes expanding the second electrode by inflating the electrode within the atria.
  • 3. A method for performing a maze procedure to treat atrial fibrillation by ablating atrial tissue to form at least one lesion in the atrial tissue, the method comprising: providing a first RF electrode coupled to one pole of an RF current source;providing a second RF electrode electrically coupled to the other pole of the RF current source;inserting the second electrode into the atrial chamber; anddisposing the first electrode against the target tissue and drawing paths with the first electrode to form the maze lesions while applying RF current between the first and second electrodes to ablate the target tissue in a maze pattern,wherein the inserting is done through an incision made to remove the right atrial appendage.
  • 4. A method as in claim 3, wherein the method does not include making any other incisions in the right atrium.
  • 5. A method as in claim 3, wherein the method does not include making an incision from the right atrial appendage incision toward the inferior vena caval orifice.
  • 6. A method as in claim 3, wherein the method does not include making a posterior longitudinal incision starting caudal to the superior caval cannulation site at the dorsal aspect of the right atrium.
Parent Case Info

This application is a divisional application of U.S. patent application Ser. No. 10/425,531 filed Apr. 29, 2003, now U.S. Pat. No. 7,497,857.

US Referenced Citations (423)
Number Name Date Kind
2371978 Perham Mar 1945 A
3496932 Prisk et al. Feb 1970 A
3736936 Basiulis et al. Jun 1973 A
3807403 Stumpf et al. Apr 1974 A
3823575 Parel Jul 1974 A
3823718 Tromovitch Jul 1974 A
3827436 Stumpf et al. Aug 1974 A
3830239 Stumpf Aug 1974 A
3854482 Laughtery et al. Dec 1974 A
3856016 Davis Dec 1974 A
3856018 Perisse et al. Dec 1974 A
3859986 Okada et al. Jan 1975 A
3862627 Hans, Sr. Jan 1975 A
3886945 Stumpf et al. Jun 1975 A
3907339 Stumpf et al. Sep 1975 A
3910277 Zimmer Oct 1975 A
3913581 Ritson et al. Oct 1975 A
3924628 Droegemueller et al. Dec 1975 A
4018227 Wallach Apr 1977 A
4022215 Benson May 1977 A
4061135 Widran et al. Dec 1977 A
4063560 Thomas et al. Dec 1977 A
4072152 Linehan Feb 1978 A
4082096 Benson Apr 1978 A
4207897 Lloyd et al. Jun 1980 A
4226239 Polk et al. Oct 1980 A
4248224 Jones Feb 1981 A
4274415 Kanamoto et al. Jun 1981 A
4275734 Mitchiner Jun 1981 A
4278090 van Gerven Jul 1981 A
4377168 Rzasa et al. Mar 1983 A
4493319 Polk et al. Jan 1985 A
4519389 Gudkin et al. May 1985 A
4598698 Siegmund Jul 1986 A
4601290 Effron et al. Jul 1986 A
4664110 Schanzlin May 1987 A
4736749 Lundback Apr 1988 A
4779611 Grooters et al. Oct 1988 A
4791707 Tucker Dec 1988 A
4802475 Weshahy Feb 1989 A
4815470 Curtis et al. Mar 1989 A
4872346 Kelly-Fry et al. Oct 1989 A
4916922 Mullens Apr 1990 A
4917095 Fry et al. Apr 1990 A
4917677 McCarthy Apr 1990 A
4936281 Stasz Jun 1990 A
4946460 Merry et al. Aug 1990 A
5013312 Parins et al. May 1991 A
5029574 Shimamura et al. Jul 1991 A
5044165 Linner et al. Sep 1991 A
5078713 Varney Jan 1992 A
5080102 Dory Jan 1992 A
5080660 Buelna Jan 1992 A
5100388 Behl et al. Mar 1992 A
5108390 Potocky et al. Apr 1992 A
5119804 Anstadt Jun 1992 A
5147355 Friedman et al. Sep 1992 A
5178133 Pena Jan 1993 A
5207674 Hamilton May 1993 A
5217473 Yoon Jun 1993 A
5217860 Fahy et al. Jun 1993 A
5222501 Ideker et al. Jun 1993 A
5224943 Goddard Jul 1993 A
5228923 Hed Jul 1993 A
5231995 Desai Aug 1993 A
5232516 Hed Aug 1993 A
5254116 Baust et al. Oct 1993 A
5263493 Avitall Nov 1993 A
5269291 Carter Dec 1993 A
5275595 Dobak, III Jan 1994 A
5277201 Stern Jan 1994 A
5281213 Milder et al. Jan 1994 A
5281215 Milder Jan 1994 A
5282829 Hermes Feb 1994 A
5295484 Marcus et al. Mar 1994 A
5309896 Moll et al. May 1994 A
5316000 Chapelon et al. May 1994 A
5317878 Bradshaw et al. Jun 1994 A
5318525 West et al. Jun 1994 A
5322520 Milder Jun 1994 A
5323781 Ideker et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324284 Imran Jun 1994 A
5324286 Fowler Jun 1994 A
5334181 Rubinsky et al. Aug 1994 A
5334193 Nardella Aug 1994 A
5334209 Yoon Aug 1994 A
5336252 Cohen Aug 1994 A
5348554 Imran et al. Sep 1994 A
5353783 Nakao et al. Oct 1994 A
5354258 Dory Oct 1994 A
5361752 Moll et al. Nov 1994 A
5366459 Yoon Nov 1994 A
5385148 Lesh et al. Jan 1995 A
5396887 Imran Mar 1995 A
5397304 Truckai Mar 1995 A
5400770 Nakao et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5403309 Coleman et al. Apr 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5423807 Milder Jun 1995 A
5423811 Imran et al. Jun 1995 A
5425740 Hutchinson, Jr. Jun 1995 A
5427119 Swartz et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5435308 Gallup et al. Jul 1995 A
5437651 Todd et al. Aug 1995 A
5443463 Stern et al. Aug 1995 A
5443470 Stern et al. Aug 1995 A
5450843 Moll et al. Sep 1995 A
5452582 Longsworth Sep 1995 A
5452733 Sterman et al. Sep 1995 A
5462545 Wang et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5469853 Law et al. Nov 1995 A
5472876 Fahy Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5478330 Imran et al. Dec 1995 A
5486193 Bourne et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5487757 Truckai et al. Jan 1996 A
5496312 Klicek Mar 1996 A
5497774 Swartz et al. Mar 1996 A
5498248 Milder Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5516505 McDow May 1996 A
5520682 Baust et al. May 1996 A
5522870 Ben-Zion Jun 1996 A
5536267 Edwards et al. Jul 1996 A
5545195 Lennox et al. Aug 1996 A
5545200 West et al. Aug 1996 A
5549661 Kordis et al. Aug 1996 A
5555883 Avitall Sep 1996 A
5558671 Yates Sep 1996 A
5560362 Sliwa, Jr. et al. Oct 1996 A
5562720 Stern et al. Oct 1996 A
5569241 Edwards Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573532 Chang et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5575788 Baker et al. Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5578007 Imran Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5590657 Cain et al. Jan 1997 A
5595183 Swanson et al. Jan 1997 A
5607462 Imran Mar 1997 A
5617854 Munsif Apr 1997 A
5620452 Yoon Apr 1997 A
5630837 Crowley May 1997 A
5637090 McGee et al. Jun 1997 A
5643197 Brucker et al. Jul 1997 A
5656029 Imran et al. Aug 1997 A
5658278 Imran et al. Aug 1997 A
5667518 Pannell Sep 1997 A
5671747 Connor Sep 1997 A
5673695 McGee et al. Oct 1997 A
5676662 Fleischbacker et al. Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5676693 Lafontaine Oct 1997 A
5678550 Bassen et al. Oct 1997 A
5680860 Imran Oct 1997 A
5681278 Igo et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5687737 Branham et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5690611 Swartz et al. Nov 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697925 Taylor Dec 1997 A
5697927 Imran et al. Dec 1997 A
5697928 Walcott et al. Dec 1997 A
5713942 Stern Feb 1998 A
5716389 Walinsky et al. Feb 1998 A
5718241 Ben-Haim et al. Feb 1998 A
5718701 Shai et al. Feb 1998 A
5720775 Larnard Feb 1998 A
5722402 Swanson et al. Mar 1998 A
5730074 Peter Mar 1998 A
5730127 Avitall Mar 1998 A
5730704 Avitall Mar 1998 A
5733280 Avitall Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5735290 Sterman et al. Apr 1998 A
5755760 Maguire et al. May 1998 A
5769846 Edwards et al. Jun 1998 A
5779699 Lipson Jul 1998 A
5782828 Chen et al. Jul 1998 A
5785706 Bednarek Jul 1998 A
5788636 Curley Aug 1998 A
5792140 Tu et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800428 Nelson et al. Sep 1998 A
5800482 Pomeranz et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5827216 Igo et al. Oct 1998 A
5836947 Fleischman et al. Nov 1998 A
5840030 Ferek-Petric et al. Nov 1998 A
5844349 Oakley et al. Dec 1998 A
5846187 Wells et al. Dec 1998 A
5846191 Wells et al. Dec 1998 A
5849028 Chen Dec 1998 A
5871523 Fleischman et al. Feb 1999 A
5871525 Edwards et al. Feb 1999 A
5873845 Cline et al. Feb 1999 A
5876399 Chia et al. Mar 1999 A
5879295 Li et al. Mar 1999 A
5879296 Ockuly et al. Mar 1999 A
5881732 Sung et al. Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5893848 Negus et al. Apr 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897553 Mulier et al. Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899898 Arless et al. May 1999 A
5899899 Arless et al. May 1999 A
5902289 Swartz et al. May 1999 A
5904711 Flom et al. May 1999 A
5906580 Kline-Schoder et al. May 1999 A
5906587 Zimmon May 1999 A
5906606 Chee et al. May 1999 A
5908029 Knudson et al. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5916214 Cosio et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5925038 Panescu et al. Jul 1999 A
5927284 Borst et al. Jul 1999 A
5928191 Houser et al. Jul 1999 A
5931810 Grabek Aug 1999 A
5931848 Saadat Aug 1999 A
5938694 Jaraczewski et al. Aug 1999 A
5954661 Greenspon et al. Sep 1999 A
5971980 Sherman Oct 1999 A
5971983 Lesh Oct 1999 A
5984917 Fleischman et al. Nov 1999 A
5989284 Laufer Nov 1999 A
5993447 Blewett et al. Nov 1999 A
6007499 Martin et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6016811 Knopp et al. Jan 2000 A
6042556 Beach et al. Mar 2000 A
6042563 Morejohn et al. Mar 2000 A
6063081 Mulier et al. May 2000 A
6071279 Whayne et al. Jun 2000 A
6088894 Oakley Jul 2000 A
6096037 Mulier et al. Aug 2000 A
6113592 Taylor Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6120496 Whayne et al. Sep 2000 A
6142993 Whayne et al. Nov 2000 A
6142994 Swanson et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6152920 Thompson et al. Nov 2000 A
6161543 Cox et al. Dec 2000 A
6165174 Jacobs et al. Dec 2000 A
6217528 Koblish et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6231518 Grabek et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6235024 Tu May 2001 B1
6237605 Vaska et al. May 2001 B1
6238347 Nix et al. May 2001 B1
6238393 Mulier May 2001 B1
6241754 Swanson et al. Jun 2001 B1
6245061 Panescu et al. Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6254598 Edwards et al. Jul 2001 B1
6270471 Hechel et al. Aug 2001 B1
6280415 Johnson Aug 2001 B1
6290674 Roue et al. Sep 2001 B1
6293943 Panescu et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6302880 Schaer Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6312383 Lizzi et al. Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6328736 Mulier Dec 2001 B1
6332881 Carner et al. Dec 2001 B1
6358248 Mulier Mar 2002 B1
6361531 Hissong Mar 2002 B1
6364876 Erb et al. Apr 2002 B1
6368275 Sliwa et al. Apr 2002 B1
6371955 Fuimaono et al. Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6385472 Hall et al. May 2002 B1
6398792 O'Connor Jun 2002 B1
6409722 Hoey Jun 2002 B1
6413254 Hissong et al. Jul 2002 B1
6416554 Alferness et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6428548 Durgin et al. Aug 2002 B1
6430426 Avitall Aug 2002 B2
6440130 Mulier Aug 2002 B1
6443952 Mulier Sep 2002 B1
6447507 Bednarek et al. Sep 2002 B1
6461314 Pant et al. Oct 2002 B1
6461356 Patterson Oct 2002 B1
6464700 Koblish et al. Oct 2002 B1
6471697 Lesh Oct 2002 B1
6471698 Edwards et al. Oct 2002 B1
6474340 Vaska et al. Nov 2002 B1
6475216 Mulier Nov 2002 B2
6477396 Mest et al. Nov 2002 B1
6484727 Vaska et al. Nov 2002 B1
6485407 Alferness et al. Nov 2002 B2
6488680 Francischelli Dec 2002 B1
6491706 Alferness et al. Dec 2002 B1
6502575 Jacobs et al. Jan 2003 B1
6514250 Jahns Feb 2003 B1
6517536 Hooven et al. Feb 2003 B2
6527767 Wang et al. Mar 2003 B2
6537248 Mulier Mar 2003 B2
6537272 Christopherson et al. Mar 2003 B2
6558382 Jahns May 2003 B2
5697536 Eggers et al. Jun 2003 C1
6584360 Francischelli Jun 2003 B2
6585732 Mulier Jul 2003 B2
6605084 Acker et al. Aug 2003 B2
6610055 Swanson et al. Aug 2003 B1
6610060 Mulier Aug 2003 B2
6613048 Mulier Sep 2003 B2
6645199 Jenkins et al. Nov 2003 B1
6648883 Francischelli Nov 2003 B2
6656175 Francischelli Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6692450 Coleman Feb 2004 B1
6699240 Francischelli Mar 2004 B2
6702811 Stewart et al. Mar 2004 B2
6706038 Francischelli Mar 2004 B2
6706039 Mulier Mar 2004 B2
6716211 Mulier Apr 2004 B2
6736810 Hoey May 2004 B2
6755827 Mulier Jun 2004 B2
6764487 Mulier Jul 2004 B2
6773433 Stewart et al. Aug 2004 B2
6776780 Mulier Aug 2004 B2
6793664 Mazzocchi et al. Sep 2004 B2
6807968 Francischelli Oct 2004 B2
6827715 Francischelli Dec 2004 B2
6849073 Hoey Feb 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6849078 Durgin et al. Feb 2005 B2
6858028 Mulier Feb 2005 B2
6887238 Jahns May 2005 B2
6899711 Stewart et al. May 2005 B2
6911019 Mulier Jun 2005 B2
6916318 Francischelli Jul 2005 B2
6936046 Hissong Aug 2005 B2
6949097 Stewart et al. Sep 2005 B2
6949098 Mulier Sep 2005 B2
6960205 Jahns Nov 2005 B2
6962589 Mulier Nov 2005 B2
7115122 Swanson et al. Oct 2006 B1
7497857 Briscoe Mar 2009 B2
20010039434 Frazier et al. Nov 2001 A1
20010039435 Roue et al. Nov 2001 A1
20020022833 Maguire Feb 2002 A1
20020022860 Borillo et al. Feb 2002 A1
20020035374 Borillo et al. Mar 2002 A1
20020049457 Kaplan et al. Apr 2002 A1
20020099390 Kaplan et al. Jul 2002 A1
20020103492 Kaplan et al. Aug 2002 A1
20020111641 Peterson et al. Aug 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020177859 Monassevitch et al. Nov 2002 A1
20030018362 Fellows et al. Jan 2003 A1
20030023266 Borillo et al. Jan 2003 A1
20030045872 Jacobs Mar 2003 A1
20030055422 Lesh Mar 2003 A1
20030060821 Hall et al. Mar 2003 A1
20030065319 Wellman Apr 2003 A1
20030144656 Ocel Jul 2003 A1
20030158464 Bertolero Aug 2003 A1
20030191462 Jacobs Oct 2003 A1
20030195496 Maguire Oct 2003 A1
20030216724 Jahns Nov 2003 A1
20040015106 Coleman Jan 2004 A1
20040015219 Francischelli Jan 2004 A1
20040044340 Francischelli Mar 2004 A1
20040049179 Francischelli Mar 2004 A1
20040073241 Barry et al. Apr 2004 A1
20040078069 Francischelli Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087940 Jahns May 2004 A1
20040092926 Hoey May 2004 A1
20040138621 Jahns Jul 2004 A1
20040138656 Francischelli Jul 2004 A1
20040143260 Francischelli Jul 2004 A1
20040186465 Francischelli Sep 2004 A1
20040215183 Hoey Oct 2004 A1
20040220560 Briscoe Nov 2004 A1
20040236322 Mulier Nov 2004 A1
20040267326 Ocel Dec 2004 A1
20050010095 Stewart et al. Jan 2005 A1
20050033280 Francischelli Feb 2005 A1
20050090815 Francischelli Apr 2005 A1
20050143729 Francischelli Jun 2005 A1
20050149068 Williams et al. Jul 2005 A1
20050149069 Bertolero et al. Jul 2005 A1
20050165392 Francischelli Jul 2005 A1
20050209564 Bonner Sep 2005 A1
20050267454 Hissong Dec 2005 A1
20050277959 Cosgrove et al. Dec 2005 A1
20060009756 Francischelli Jan 2006 A1
20060009759 Christian Jan 2006 A1
20060020271 Stewart et al. Jan 2006 A1
Foreign Referenced Citations (8)
Number Date Country
9962409 Dec 1999 WO
0135832 May 2001 WO
0187169 Nov 2001 WO
0197696 Dec 2001 WO
02087456 Nov 2002 WO
03011150 Feb 2003 WO
03096881 Nov 2003 WO
2004096070 Nov 2004 WO
Related Publications (1)
Number Date Country
20090138008 A1 May 2009 US
Divisions (1)
Number Date Country
Parent 10425531 Apr 2003 US
Child 12364232 US